Armistice Capital, LLC Exact Sciences Corp Transaction History

Armistice Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$41.33 - $74.26 $27.7 Million - $49.7 Million	669,438 Added 91.62%	1,400,086 $59.2 Million
Q1 2024 May 15, 2024	SELL	$56.27 - $73.77 $2.32 Million - $3.04 Million	-41,173 Reduced 5.33%	730,648 $50.5 Million
Q4 2023 Feb 13, 2024	BUY	$59.06 - $75.72 $3.56 Million - $4.57 Million	60,301 Added 8.47%	771,821 $57.1 Million
Q3 2023 Nov 14, 2023	BUY	$65.94 - $99.04 $15.8 Million - $23.7 Million	239,520 Added 50.75%	711,520 $48.5 Million
Q2 2023 Aug 14, 2023	SELL	$62.68 - $95.05 $55.4 Million - $84 Million	-884,000 Reduced 65.19%	472,000 $44.3 Million
Q1 2023 May 15, 2023	SELL	$47.19 - $70.77 $8.49 Million - $12.7 Million	-180,000 Reduced 11.72%	1,356,000 $92 Million
Q4 2022 Feb 14, 2023	SELL	$30.35 - $53.15 $728,400 - $1.28 Million	-24,000 Reduced 1.54%	1,536,000 $76 Million
Q3 2022 Nov 14, 2022	BUY	$31.97 - $49.37 $49.9 Million - $77 Million	1,560,000 New	1,560,000 $50.7 Million
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $3.98 Million - $5.68 Million	-40,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$72.92 - $102.01 $2.92 Million - $4.08 Million	40,000 New	40,000 $4.08 Million

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.